Company news
Gossamer Bio, Inc. news in 2022
Gossamer Bio, Inc.'s news releases, calls and decks from 2022, newest first.
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
December 5, 2022
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
November 2, 2022
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
August 8, 2022
Gossamer Bio Announces $120 Million Private Placement Financing
July 12, 2022
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
June 8, 2022
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
May 9, 2022
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
April 24, 2022
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
March 2, 2022
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
February 27, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (December 2022)
Technical · 39 slides · Dec 6, 2022